Glenmark To Launch Cancer Drug Brukinsa In India

Glenmark Pharmaceuticals said Monday it will launch Zanubrutinib in India under the brand name Brukinsa after receiving approval from the Drugs Controller General of India.

Brukinsa, developed by Switzerland-based BeOne Medicines (formerly BeiGene), is the first and only Bruton's tyrosine kinase inhibitor approved in India to treat five types of B-cell cancers—chronic lymphocytic leukaemia/small lymphocytic lymphoma,

Waldenstrom macroglobulinaemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma.
The launch marks a key addition to Glenmark’s oncology portfolio, bringing a globally used advanced treatment to the Indian market.